ALMR · GSK proteomics collaboration

Alamar Biosciences announced a strategic scientific collaboration with GSK to use its NULISA platform for large-scale proteomic profiling of over 60,000 serum samples across multiple disease areas. The deal provides validation for Alamar's technology but does not disclose financial terms, limiting immediate revenue visibility.

• Collaboration with GSK to analyze >60,000 serum samples using Alamar's NULISAseq panels
• Focus areas include proteomic correlates of disease outcomes, biomarker identification, mechanistic endotyping, and drug response
• No financial terms (upfront, milestones, or royalties) disclosed in the press release
• Alamar reported Q3 2026 revenue of $33.5M (+68% YoY) and raised full-year guidance to $121M-$123M in a separate 8-K filed the same day